

Study: ENGOT-ov77/ DS6000-109

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active **
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
MB	Monza	Ospedale San Gerardo	Andrea A. Lissoni	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	

* **MaNGO Principal Investigator: to be defined**

** **MaNGO sites list: to be confirmed by Sponsor**